Rein Therapeutics (RNTX) Leases (2019 - 2022)
Rein Therapeutics (RNTX) has disclosed Leases for 4 consecutive years, with $40000.0 as the latest value for Q4 2022.
- Quarterly Leases fell 73.68% to $40000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $40000.0 through Dec 2022, down 73.68% year-over-year, with the annual reading at $40000.0 for FY2022, 73.68% down from the prior year.
- Leases for Q4 2022 was $40000.0 at Rein Therapeutics, down from $70000.0 in the prior quarter.
- The five-year high for Leases was $6.5 million in Q1 2019, with the low at $40000.0 in Q4 2022.
- Average Leases over 4 years is $2.9 million, with a median of $228000.0 recorded in 2021.
- The sharpest move saw Leases dropped 9.93% in 2020, then plummeted 96.81% in 2021.
- Over 4 years, Leases stood at $6.1 million in 2019, then decreased by 8.42% to $5.6 million in 2020, then tumbled by 97.26% to $152000.0 in 2021, then crashed by 73.68% to $40000.0 in 2022.
- According to Business Quant data, Leases over the past three periods came in at $40000.0, $70000.0, and $98000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.